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ABSTRACT
Human chorionic gonadotropin (hCG) is a clinically relevant marker
of trophoblastic and nontrophoblastic malignancies. In the present stud
ies, in addition to determining serum hCG, we investigated the presence
and properties of hCG immunoreactivity in ascites of patients with
nontrophoblastic malignant tumors and, for comparison, in ascites caused
by cirrhotic liver disease. Total hCG immunoreactivity |hCG (+hCG-/3)|
was found to be elevated above the reference value (>S ID/liter) in the
serum of 2 of 20 patients with cirrhosis and 11 of 20 patients with
malignant tumors. For comparison, in ascites, hCG (+hCG-0) concentra
tions were frequently higher than in the corresponding serum samples
and exceeded 10 II /liter in 0 of 20 cirrhotic samples and in 16 of 20
malignant samples.
In order to elucidate the nature of the hCG immunoreactive material,
all samples were then assessed by immunoradiometric assays specific for
the intact hCG molecule (holo-hCG) and the free hCG-0 subunit, respec
tively. In the holo-hCG assay, elevated values were detected in 0 of 20
(0 of 20) cirrhotic ascites (serum) samples and 0 of 20 (1 of 20) malignant
ascites (serum) samples. In the free hCG-0 assay, on the other hand, no
positive results were obtained in the ascites or serum of 20 patients with
liver cirrhosis; however, 8 of 20 serum samples and 16 of 20 ascites
samples derived from tumor patients were positive. In accord with the
immunological data, gel chromatographical studies of malignant ascites
revealed the abundance of free hCG-0 subunit rather than that of holo-
hCG. In contrast to malignancy-related ascites, in ascites of patients
receiving hCG injections for treatment of infertility, holo-hCG was more
abundant than free hCG-0 immunoreactivity. Incubation experiments of
purified holo-hCG in ascites for 24 h at -20, 20, or 37Â°Cshowed no
substantial dissociation of the hCG molecule and release of free hCG-/3
immunoreactivity, thus arguing against production of free hCG-/3 by
degradation of holo-hCG and in favor of its tumor-related secretion.
In conclusion, h< (,~/f immunoreactivity is frequently elevated in ma
lignancy-related ascites and appears to be related to the presence of free
/; subunit of hCG rather than that of the intact hCG molecule. Interest
ingly, hCG-0 determination in ascites proved to be clearly superior to
serum measurement in discriminating between tumor and cirrhosis. Thus,
hCG-0 might be a useful marker of malignancy-related ascites and should
be prospectively assessed for possible clinical use in comparison with
other well-established parameters, such as cytology and protein deter
mination. For this purpose, according to our results, only assays that
exhibit a high sensitivity for free hCG-0 subunit appear to be suitable.
INTRODUCTION
hCG1 is a glycoprotein hormone with a molecular weight of
38,000 which is made up of two dissimilar noncovalently linked
subunits, termed a- and ÃŸ-subunit(l). Furthermore, the hCG
molecule contains a relatively high amount of carbohydrate that
makes up approximately 30% of its weight (2). Apart from its
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physiological role in maintaining corpus luteum function during
human pregnancy, hCG is secreted by tumors of trophoblastic
origin and, therefore, has long been used as an important tumor
marker for the diagnosis and management of patients with
testicular cancer (3-8). In addition, serum hCG immunoreac
tivity has been reported to be elevated in a significant portion
of patients with various nontrophoblastic malignancies, such as
cancers of the ovary, cervix, gastrointestinal tract, lung, and
breast (9). In this respect, most studies have focused on serum
determinations, whereas hCG immunoreactivity in other body
fluids, such as ascites, has received scant attention. The detec
tion of malignancy-related ascites, however, is of considerable
clinical importance, and the currently used markers, such as
cytological examination and protein determination, are not very
efficient in separating benign from malignant ascites (10, 11).
We have therefore undertaken the present studies to evaluate
the presence and properties of immunoreactive hCG in malig
nancy-related ascites. To this end, we determined hCG immu
noreactivity in both serum and ascitic fluid of patients with
various malignant tumors and, for comparison, in patients with
cirrhotic liver disease. In addition, in order to further elucidate
the nature of the hCG immunoreactivity, the samples were
assessed by immunoradiometric assays that specifically recog
nize holo-hCG and the free ÃŸsubunit of hCG, respectively.
Finally, the hCG immunoreactive material present in malignant
ascites was characterized by gel chromatography.
MATERIALS AND METHODS
Highly purified preparations of intact hCG (CR121) and the 0-
subunit of hCG (CR123-0) were supplied by the Hormone Distribution
Program of the National Institute of Diabetes and Digestive and Kidney
Diseases. The third International Reference Preparation 75/537 for
hCG and the first International Reference Preparation 75/551 for the
ÃŸsubunit of hCG used for standardization of IRMAs were kindly
provided by the National Institute for Biological Standards (London,
United Kingdom).
mab 11/6 (against holo-hCG and holo-LH), mab 3/6 [against hCG
(+hCG-/3)], mab 12/17 [against hCG (+hCG-0), different epitope from
that recognized by mab 3/6], and mab 2/6 (specific for free hCG-/8
subunit) were kindly donated by Dr. K. Siddle (University of Cam
bridge, Cambridge, United Kingdom). They had been raised in BALB/
c mice and characterized as described previously (12).
Patients
Patients with Liver Cirrhosis. Group I consisted of 20 patients with
ascites due to cirrhotic liver disease (13 men, 7 women; age, 28-79
years; mean Â±SD, 56 Â±13 years). Diagnosis had been established in
these patients by liver biopsy and histolÃ³gica! examination. With re
spect to the etiology of liver disease, 12 patients had alcoholic cirrhosis
and 6 patients had posthepatitic liver cirrhosis. Other causes included
primary biliary cirrhosis (n = 1) and Budd-Chiari syndrome (n = 1).
Patients with Malignant Tumors. Group II consisted of 20 patients
with advanced malignant diseases and ascites (7 men, 13 women). Their
mean age was 57 Â±13 years (range, 33-80 years). In all patients,
histolÃ³gica! proof of the primary tumor was obtained and diagnoses
were as follows: carcinomas of the breast (n = 4), stomach (n = 3),
colon (n = 3), pancreas (n = 1), ovary (n = 3), cervix (n = 2), and
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bladder (n = 1); hepatocellular carcinoma (n = 1); carcinoid (n = 1);
and adenocarcinoma of unknown origin (n = I).
Patients Treated with hCG. Ascites samples were obtained from two
29-year-old women who had received hCG injections for treatment of
infertility and developed ascites due to ovarian overstimulation.
HOC Determinations
Three specific IRMAs, which were previously been described and
characterized in detail (13-15), were used to measure total hCG-related
immunoreactivity [hCG (+hCG-j3)] in serum and ascites and to discrim
inate between the presence of holo-hCG and free hCG-/3.
The hCG (+hCG-/3) IRMA uses mab 3/6 and mab 12/17 and
recognizes the .)'subunit of hCG in its combined form within the holo-
hCG molecule as well as in its free form (cross-reactivity of 720% on a
molar basis).
The holo-hCG IRMA utilizes mab 3/6 and mab 11/6 and measures
the intact hCG molecule with negligible cross-reactivity with free hCG-
ÃŸsubunit (<0.01%) and other pituitary hormones (15).
The free hCG-0 IRMA with mab 2/6 and mab 12/17 is highly
specific for the free ÃŸsubunit of hCG and exhibited cross-reactivities
of 0.36-2.7% with purified holo-hCG from various sources (15, 16).
The assays use two monoclonal antibodies each and were carried out
by coupling the first antibody (dilution 1:5000 of native ascitic fluid in
50 mmol/liter ammonium bicarbonate, pH 8.0) to polystyrene tubes
(Star-Tubes; Nunc, Wiesbaden, Germany) and using the second anti
body as '"I-labeled tracer (Chloramine-T method)(14). The antibody-
coupled tubes were incubated with 100 ^1 of serum or ascites and 100
n\ of IRMA buffer (phosphate-buffered saline containing 1% bovine
serum albumin) under constant shaking at room temperature for 2 h.
After the tubes were washed twice with 10 mmol/liter Tris-Cl buffer,
pH 8.0 (1 ml), containing 0.05 g Tween-20/liter, incubation with the
'"I-labeled second antibody (approximately 100,000 cpm; 2-3 ng in
100 n\) was performed under the same conditions. After the tubes were
again washed, the radioactivity bound was determined by the use of a
gamma counter (Multigamma; LKB, Freiburg, Germany).
The hCG (+hCG-/3) IRMA and the holo-hCG IRMA were standard
ized at the third International Reference Preparation for hCG, while
the free hCG-j3 IRMA was standardized with the first International
Reference Preparation for hCG-/3. For that reason, results expressed in
IU/liter have a different meaning for the different assays and are not
to be compared directly among the assays. For comparison, 1 ng holo-
hCG (NIH CR121) showed an immunoreactivity of 10 mlU in the hCG
(+hCG-j3) IRMA and of 8 mlU in the holo-hCG IRMA. On the other
hand, 1 ng hCG-/3 (NIH CR123-/3) displayed an immunoactivity of 60
mlU in the hCG (+hCG-/3) assay and of 1.6 mlU in the free hCG-0
assay.
Reference values for ascites were not known for any of the assays
prior to the present study and were defined according to the results
obtained in cirrhotic ascites samples. Reference values for serum are
given in Table 1.
The analytical performance of the assays was reported in detail
previously (14). Briefly, the coefficients of intraassay variation were
between approximately 5 and 10% at different concentrations, and the
interassay coefficients of variation ranged between 9 and 13%.
Chromatography of Ascites on a Column of AcA 44
To separate holo-hCG and its subunits, ascites samples obtained
from two patients with carcinoma of the bladder and hepatocellular
carcinoma (0.5 ml) containing large amounts of hCG (+hCG-/3) im
munoreactivity (14,492 and 50,422 IU/liter) were directly applied to a
column of Ultrogel AcA 44 (Serva, Heidelberg, Germany) (1 x 100 cm)
preequilibrated with 0.01 M Tris-Cl, 0.15 M NaCl, pH 8.O. Fractions
obtained upon eluting the column with the same buffer were measured
by specific holo-hCG and free hCG-/3 IRMA as described above. The
column was calibrated by dextran blue and several molecular weight
markers. In some experiments, elution of l25I-hCG was studied concom-
itantly. The elution position of hCG-0 subunit (CRI23-0) was deter
mined in a separate experiment after chromatography of ascites.
Table 1 Limits of detection and reference values for serum for hCG assays
Solid phase Tracer
Limit ofdetection" Reference value(IU/liter)
hCG (+hCG-/3) IRMA mab 3/6
holo-hCG IRMA mab 3/6
free hCG-0 IRMA mab 2/6
mab 12/17 2 IU/liter <5
mab 11/6 2 IU/liter <5
mab 12/17 0.05 IU/liter <0.2
" Limits of detection, the concentration interpolated from the curve at 3 SD
above the zero point.
* Reference values, obtained by using the 95th percentile of 200 normal subjects
of both sexes including 46 postmenopausal women.
Incubation Experiments of hCG in Ascites
To determine its stability, a defined amount of holo-hCG (CR121)
was added to an hCG (+hCG-/3) negative ascites sample, a control
serum, and the IRMA buffer (phosphate-buffered saline containing 1%
bovine serum albumin). The samples were kept at -20, 20, or 37"C for
24 h and then measured by hCG (-t-hCG-0) IRMA, holo-hCG IRMA,
and free hCG-/3 IRMA. In other experiments, dilution and recovery of
hCG immunoreactivities in ascites were studied.
Statistical Methods
For statistical analysis of data, Wilcoxon tests for paired or unpaired
observations were used.
RESULTS
hCG Determinations in Serum. Initially, total hCG-related
immunoreactivity was assessed in the sera from patients by
hCG (+hCG-/3) IRMA that recognizes the ÃŸsubunit of hCG in
its free form as well as in the holo-hCG molecule. Levels above
normal (>5 IU/liter) were found in 2 of 20 (10%) patients with
liver cirrhosis (group I) and in 11 of 20 (55%) patients with
malignancies (group II). Serum concentrations of both intact
holo-hCG and free hCG-/3 subunit immunoreactivity were then
determined in the two groups of patients by the use of the two
specific IRMAs described in "Materials and Methods." The
data are shown in Fig. 1. In group I, values above the normal
range for holo-hCG were found in 0 of 20 patients and, for free
ÃŸsubunit of hCG, in 1 of 20 (5%) patients. In group II, on the
other hand, holo-hCG was elevated in 1 of 20 (5%) patients,
and hCG-j3 was elevated in 8 of 20 (40%) patients.
hCG Determinations in Ascites. hCG (+hCG-/3) immunoreac
tivities were mostly higher in ascites as compared to serum
values, particularly in tumor patients. Fig. 2 shows the corre
sponding results in serum and ascites for each patient.
Furthermore, in ascites samples derived from patients with
malignant diseases, significantly higher hCG (+HCG-/3) activi
ties were found than in samples from patients with liver cirrho
sis (median, 19.1 versus 2.2 IU/liter, P < 0.01). When 10 IU/
liter was defined as the upper limit of the normal range, 20 of
20 (100%) of the cirrhotic ascites samples were judged to be
normal and 16 of 20 (80%) of the malignant ascites samples
were considered pathological (Fig. 3).
Further assessment of the same samples by the more specific
IRMAs against holo-hCG and free hCG-/3 revealed that eleva
tion of hCG (+hCG-0) activity was caused by the presence of
free hCG-ÃŸactivity rather than that of holo-hCG (Fig. 3).
In malignant ascites, immunoactivities of free hCG-ÃŸranged
between <0.05 and 102 IU/liter (median, 0.85 IU/liter) and
were elevated >0.2 IU/liter in 16 of 20 (80%) samples. Holo-
hCG immunoactivities, on the other hand, were undetectable
in 17 of 20 (85%) malignant ascites samples and exceeded the
normal range (>5 IU/liter) only in one case. For comparison,
the 20 cirrhotic ascites samples showed all normal free hCG-/3
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Fig. \. Determination of hCG (+hCG-0), holo-hCG, and free hCG-0 immu-
noreactivities in serum of patients with cirrhotic liver disease and malignant
tumors. Three specific IRMAs were used to determine total hCG-0-related
immunoreactivity [hCG (+HCG-0)] and to distinguish between the presence of
the holo-hCG or the free hCG-/3. Immunoreactivities for hCG (+hCG-/3), holo-
hCG, and free h( (, .; were elevated in 2 of 20, 0 of 20, and 1 of 20 patients with
cirrhosis and 11 of 20, 1 of 20, and 8 of 20 patients with malignant tumors,
respectively. Big circles, the specified number of values that were below the
detection limit of the assay; dashed lines, the upper limit of the normal range of
each assay. Note that a different scale was used for free hCG-/3. Also, because of
different standardization of the assays with hCG or hCG-0, results expressed in
IU/liter have a different meaning for each assay and are not directly comparable
among the IRMAs (see "Materials and Methods").
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Fig. 2. Comparison of hCG (+hCG-j3) immunoreactivities in astiles and
corresponding serum samples of patients with cirrhotic liver disease and malig
nant tumors. The data show that hCG (+hCG-0) concentrations are frequently
higher in ascites than serum. Statistical evaluation by Wilcoxon signed rank test:
for cirrhosis, n = 20, P > 0.05; for tumor group, n = 20, P < 0.001).
activities (<0.2 IU/liter) ranging from <0.05 to 0.18 IU/liter
(median, <0.05 IU/liter), as well as normal, mostly undetecta-
ble holo-hCG activities (Fig. 3).
In contrast to malignancy-related ascites samples, ascites
samples obtained from two women who had received hCG
injections and developed ascitic fluid due to ovarian oversti-
mulation displayed elevated activities of both holo-hCG (65.5
and 21.2 IU/liter) and free HCG-/3 subunit (0.59 and 0.48 IU/
liter). Corresponding serum values were 139 and 11 IU/liter,
respectively, for holo-hCG and 0.38 and 0.22 IU/liter, respec
tively, for free hCG-/3.
Identification of Free hCG-/3 in Malignant Ascites. Two ascites
samples from patients with carcinoma of the bladder and hep-
atocellular carcinoma were selected on the basis of highly
elevated hCG (+hCG-/3) immunoreactivities and subjected to
gel chromatography on a column of AcA 44, as described in
"Materials and Methods" (Fig. 4). Fractions eluted from the
column were measured by specific holo-hCG and specific free
hCG-/3 IRMA, respectively. They contained a significant
amount of free hCG-/8 activity, whereas any appreciable activity
of intact holo-hCG was lacking. Furthermore, the position of
elution of the hCG-/3 immunoreactive material in ascites was
virtually identical with that of purified hCG-/3 subunit (NIH
CR123-/3) of pregnancy origin and clearly distinguishable from
the l25I-holo-hCG elution pattern.
In order to determine its stability in various media, purified
holo-hCG was added to ascites, serum, and IRMA buffer. After
the samples were incubated at different temperatures (â€”20,20,
37'C) for 24 h, hCG (+hCG-/3), holo-hCG, and free hCG-0
immunoreactivities were measured. The results are shown in
Fig. 5. As can be seen, there was no substantial dissociation of
holo-hCG into its subunits under these conditions, although at
37Â°Ca small increase in free hCG-/3 activity was detectable in
all three media.
Dilution of highly positive malignant ascites samples, as well
as of ascites samples to which holo-hCG- or hCG-/3 standard
preparations had been added, resulted in a linear decrease of
immunoreactivities measured (data not shown). Furthermore,
dose-response curves of holo-hCG and hCG-j3 standards proved
to be parallel in serum and ascites in holo-hCG and free hCG-
ÃŸIRMA, respectively. Also, recoveries of holo-hCG and hCG-
ÃŸin ascites were similar to those in serum (data not shown).
DISCUSSION
In the present study we evaluated the presence and nature of
hCG immunoreactivity in serum and ascites of patients with
various malignant tumors and, for comparison, patients with
cirrhotic liver disease.
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Fig. 3. Determination of hCG (-r-hCG-0), holo-hCG, and free hCG-0 immu
noreactivities in ascites of patients with cirrhotic liver disease and malignant
tumors (see legend to Fig. I). Immunoreactivities for hCG (+hCG-/)), holo-hCG,
and free hCG-/3 were elevated in 0 of 20, 0 of 20, and 0 of 20 patients with
cirrhosis and 16 of 20, 1 of 20, and 16 of 20 patients with malignant tumors,
respectively.
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Fig. 4. Chromatograph? on an AcA 44 column of ascites obtained from a
patients with carcinoma of the bladder. The data indicate the abundance of freehC"G-j)subunit in the absence of holo-hCG in this ascites sample. Native ascites
(0.5 ml) containing 14,492 IU/liter of hCG (+hCG-0) immunoreactivity and 203
U /liter of free hCG-0 activity was applied to the column. Upon eluting with 0.01
M Tris-CI, 0.15 M NaCl (pH 8.0), fractions were measured by IRMAs specific for
holo-hCG and free hCG-0 subunit. Arrows, elution positions of '"I-holo-hCG,
free hCG-/3, and molecular weight markers jdextran for detection of void volume
(Vo); bovine serum albumin (BSA), M, 67,000; cytochrome, M, 12,000; and
vitamin (vit.) BU M, 1,200]. Please note that limits of detection of the two assays
are different and that their results are not directly comparable on the basis of theI! '/liter values, because those relate to different standards (see "Materials and
Methods").
In accord with previous reports (9, 17-22), serum concentra
tions of total hCG-related immunoreactivity [holo-hCG or free
hCG-/3 subunit, hCG (+hCG-/3)] were elevated above the normal
range in a substantial fraction of our tumor patients (55%). In
comparison, elevated serum hCG (+hCG-/3) activity was rare
in patients with liver cirrhosis (2 of 20,10%). More interesting,
however, we found that hCG (+hCG-/3) immunoreactivities in
patients with malignancies were usually higher and more often
elevated in ascites as compared to serum. The differences could
not be accounted for by the use of different media, since dose-
response curves showed parallel behavior in serum and ascites,
and recovery of hCG standard preparations was comparable in
the two media (data not shown). As a result, measurements in
ascites were superior to serum determinations in discriminating
between tumor patients and patients with cirrhosis. At a cutoff
value of 10 IU/Hter, hCG (+hCG-/3) determination correctly
identified 80% of tumor samples and 100% of cirrhotic ascites
samples. There have apparently been no reports in the literature
on the value of hCG determination in ascites of tumor patients
as compared to serum assessment. With respect to hCG meas
urement in malignant effusions, a few studies are available (23-
25). Couch (23) reported a sensitivity of 36% for hCG (+hCG-
ÃŸ)(>10 IU/liter) in malignant ascites, which is much lower
than our data indicate.
This discrepancy may be due to the following reasons. There
may be differences between the study groups regarding type and
stage of tumors. Furthermore, the IRMA technique generally
offers an enhanced sensitivity compared to formerly used radio-
immunoassay methods. Finally, the particular hCG (+hCG-/J)
IRMA we have used in the present study has a remarkably high
cross-reactivity with free 0-subunit of hCG (720%), which is
not reached by most commercially available hCG (+hCG-/8)
kits (14). In that respect, we could previously demonstrate that
the use of such an assay yielded a higher sensitivity in certain
types of cancer, such as hCG-positive seminoma, in which free
hCG-ÃŸsubunit secretion by the tumor occurs in the absence of
holo-hCGproduction(13, 14).
In addition to measuring total hCG-related immunoreactiv
ity, we were particularly interested in further elucidating the
nature of this material. To this end, ascites samples containing
large amounts of hCG (+hCG-/3) immunoreactive material were
subjected to gel chromatography. The material showed a pat
tern of elution very similar to that of the free ÃŸsubunit of hCG
as opposed to holo-hCG. Furthermore, it exhibited a strong
immunoreactivity in our IRMA that recognizes specifically the
free ÃŸsubunit of hCG and does not appreciably cross-react with
holo-hCG; whereas there was no activity in an IRMA specific
for holo-hCG. These findings suggested that free hCG-/3 activity
was more abundant in malignant ascites than holo-hCG.
All ascites samples were then directly measured by the two
IRMAs specific for free hCG-ÃŸand for holo-hCG. Reference
values for each assay were defined on the basis of the results
obtained in cirrhotic ascites samples. Cutoff values of 0.2 IU/
liter for free hCG-0 and 5 IU/liter for holo-hCG yielded nega
tive results in all 20 cirrhotic ascites samples. Using these
reference values, we found that free hCG-ÃŸactivity was elevated
in 80% of malignant ascites samples. In contrast, holo-hCG
immunoactivity was negative in all but one of the malignant
ascites samples tested.
Presence of free hCG-0 in ascites is unlikely to be due to
release from the holo-hCG molecule, as indicated by the follow
ing observations: (a) incubation experiments with purified holo-
hCG failed to detect a meaningful subunit dissociation in as
cites, and (b) more important, in ascites samples obtained from
women who had received hCG injections for therapeutic rea
sons and who developed ascites due to ovarian overstimulation,
representing a model of in vivo incubation of hCG, holo-hCG
-20C
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Fig. 5. Incubation of holo-hCG in ascites, serum, and IRMA buffer. A defined
amount of purified holo-hCG (NIH CR121) was incubated in the various media
for 24 h at â€”¿20.20, or 37'C, and the samples were subsequently measured by
IRMAs specific for hCG (+hCG-0), holo-hCG, and free hCG-/3. The data show
a small increase in free hCG-/3 activity in all three media at 37*C incubation but
no substantial dissociation of holo-hCG into its subunits under any condition.
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(not free HCG-/3) was preferentially detectable. The prevalence
of free hC'G-d in malignant ascites, on the other hand, was
consistent with the pattern in the sera of our tumor patients in
which free hCG-ÃŸwas detectable more often than holo-hCG.
For those reasons, we assume that secretion by the tumor cells
of free ÃŸsubunit may occur independently of holo-hCG, as has
been reported for seminoma and other solid tumors (13, 14,
26, 27).
In conclusion, the present data indicate that hCG-0 immu-
noactivity is frequently elevated in malignancy-related ascites,
and, with respect to the nature of the material, free hCG-/3
subunit rather than holo-hCG is abundant. Remarkably, hCG-
ÃŸconcentrations were higher in the ascites than in the serum
of tumor patients, and hCG-ÃŸdetermination in ascites was
superior to serum measurement in discriminating between cir
rhosis and tumor.
As for the clinical implications of this study, hCG-i? could
possibly be a marker of malignancy-related ascites. In this
respect, our preliminary data seem to be promising but need to
be confirmed in another larger prospective study which should
clarify the role of hCG-ÃŸin comparison with other well-estab
lished parameters, such as cytological examination or measure
ments of protein, cholesterol, and fibronectin (10, 11, 28, 29).
The sensitivity of this marker, however, may depend on the
method used for hCG determination, and, according to our
results, only assays that exhibit a high sensitivity for the free ÃŸ
subunit of hCG, but not assays that specifically recognize the
holo-hCG molecule, can be recommended.
REFERENCES
1. Pierce, J. G., and Parsons, T. F. Glycoprotein hormones, structure and
function. Annu. Rev. Biochem., 50:465-495, 1981.
2. Kahl. O. P. Human chorionic gonadotropin. II. Nature of the carbohydrate
units. J. Biol. Chem., 244: 575-583, 1969.
3. Zondek, B. Versuch einer biologischen (hormonalen) Diagnostik beim malig
nen Hodentumor. Chirurg, 2:1072-1073, 1930.
4. Anderson, T., Glatstein, E., Javadpour, N., and Waldmann, T. A. Testicular
germ-cell neoplasmas: recent advances in diagnosis and therapy, NIH con
ference. Ann. Intern. Med., 90: 373-385, 1979.
5. Bagshawe, K. D. Tumor-associated antigens. Br. Med. Bull., 30: 68-73,
1974.
6. Barzell, W. E., and Whitmore, W. F. Clinical significance of biologic markers:
Memorial hospital experience. Semin. Oncol., 6:48-52, 1979.
7. Javadpour, N. The role of biologic tumor markers in testicular cancer. Cancer
(Phila.), 45:1755-1761, 1980.
8. Norgaard-Pedersen, B., and Raghavan, D. Germ cell tumors: a collaborative
review. Oncodev. Biol. Med., /: 327-358, 1980.
9. Hussa, R. O. Human chorionic gonadotropin, a clinical marker: review of its
biosynthesis. Ligand Rev., ) (Suppl. 2).-6-44, 1981.
10. Tomb, J. A cytological study on serous fluid in cancer. Lab. Med. J., 27: 51-
58, 1974.
11. Garrison, R. N., Kaelin, L. D., Hauser, L. S., and Galloway, R. H. Malignant
ascites. Clinical and experimental observations. Ann. Surg., 2113:644-651,
1986.
12. Siddle, K., Gard, T., Thomas, D., Cranage, M. P., and Coombs, R. R. A.
Red cell-labelled monoclonal antibodies for assay of human chorionic gonad
otropin and luteinizing hormone by reverse passive haemagglutination. J.
Immunol. Methods, 73: 169-176, 1984.
13. Mann, K., and Siddle, K. Evidence for free beta-subunit secretion in so called
hCG-positive seminoma. Cancer (Phila.), 62:2378-2382,1988.
14. Sailer, B., Clara, R., Spoettl, G., Siddle, K., and Mann, K. Testicular cancer
secretes intact human choriogonadotropin (hCG) and its free /9-subunit:
evidence that hCG (+ hCG-/3) assays are the most reliable in diagnosis and
follow-up. Clin. Chem., 36:234-239, 1990.
15. Hoermann, R., Spoettl, G., Moncayo, R., and Mann, K. Evidence for the
presence of human chorionic gonadotropin (hCG) and free (3-subunit of hCG
in the human pituitary. J. Clin. Endocrino!. Metab., 71:179-186, 1990.
16. Sailer, B., Hoermann, R., Spoettl, G., and Mann, K. Measurement of free
choriogonadotropin /9-subunit in patients with testicular tumors (letter). Clin.
Chem., 36: 2009, 1990.
17. Donaldson, E. S., van-Nagell, J. R., Jr., Pursell, S., Gay, E. C, Meeker, W.
R., Kashmiri, R., and van-deVoorde, J. Multiple biochemical markers in
patients with gynecologic malignancies. Cancer (Phila.), 45: 948-953, 1980.
18. Gropp, C., Havemann, K., and Scheuer, A. Ectopie hormones in lung cancer
patients at diagnosis and during therapy. Cancer (Phila.), 46:347-354,1980.
19. Das, S., Mukherjee, K., Bhattacharya, S., and Chowdhury, J. R. Ectopie
production of placenta! hormones (human chorionic gonadotropin and hu
man placenta! lactogen) in carcinoma of the uterine cervix. Cancer (Phila.),
51:1854-1857, 1983.
20. Avala, A. R., Saad, A., Vazquez, X., Ramirez-Wiella, G., and Perches, R. D.
Human chorionic gonadotropin immunoreactivity in serum of patients with
malignant neoplasms. Am. J. Reprod. Immunol., 3:149-151, 1983.
21. Borkowski, A., Puttaert, V., Gyling, M., Muquardt, C. and Body, J. J.
Human chorionic gonadotropin-like substance in plasma of normal nonpreg-
nant subjects and women with breast cancer. J. Clin. Endocrino!. Metab.,
58:1171-1178, 1984.
22. Iles, R. K., Lee, C. L., Oliver, R. T., and Chard, T. Composition of the intact
hormone and free subunits in the human chorionic gonadotropin-like mate
rial found in serum and urine of patients with carcinoma of the bladder. Clin
. Endocrino!. (Oxf.), 33: 355-364, 1990.
23. Couch, W. D. Combined effusion fluid tumor marker assay, carcinoem-
bryonic antigen (CEA) and human chorionic gonadotropin (hCG), in the
detection of malignant tumors. Cancer (Phila.), 48:2475-2479, 1981.
24. Hattori, M., Yoshimoto, Y., Matsukura, S., and Fujita, T. Qualitative and
quantitative analyses of human chorionic gonadotropin and its subunits
produced by malignant tumors. Cancer (Phila.), 46:355-361, 1980.
25. Pavesi, F., Lotzniker, M., Cremasela, P., Marbello, L., Acquistapace, L., and
Morati!. R. Detection of malignant pleura! effusions by tumor marker
evaluation. Eur. J. Cancer. Clin. Oncol., 24: 1005-1011, 1988.
26. Papapetrou, P. D., and Nicopoulou, S. C. The origin of a human chorionic
gonadotropin beta-subunit-core fragment excreted in the urine of patients
with cancer. Acta Endocrino!. Copenh., 112:415-422, 1988.
27. Cole, L. A., Hussa, R. O.. and Rao, C. V. Discordant synthesis and secretion
of human chorionic gonadotropin and subunits by cervical carcinoma cells.
Cancer Res., 41:1615-1619, 1981.
28. Juengst, D., Gerbes, A. L., Martin, R., and Paumgartner, G. Value of ascitic
lipids in the differentiation between cirrhotic and malignant ascites. Hepa-
tology, 6: 239-243, 1986.
29. Gerbes, A. L., Xie, Y., Mezger, J., and Juengst, D. Ascitic fluid concentra
tions of fibronectin and cholesterol: comparison of differential diagnostic
value with conventional protein determination. Liver, 10:152-157, 1990.
1524
